Altimmune (ALT)
(Real Time Quote from BATS)
$6.66 USD
-0.60 (-8.26%)
Updated Apr 29, 2024 12:47 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALT 6.66 -0.60(-8.26%)
Will ALT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALT
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Other News for ALT
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ALT, CYCC and DB among pre-market losers
Altimmune downgraded to Neutral at Guggenheim on pemvidutide's uncertain future
Guggenheim gets more bearish on Altimmune, downgrades shares
Roche: Value Remains Despite Covid-19 Revenue Growth Loss